The U.S. Food and Drug Administration found that Johnson & Johnson’s single dose vaccine is 66% effective in preventing a moderate to severe case of Covid-19. It was also found to be safe and resulted in no deaths.
This finding paves the way for the vaccine to be authorized in the United States as early as this weekend.
The company conducted a study of 44,000 patients in the U.S., South Africa, and other countries and determined that its single shot vaccine was highly effective for prevention against severe Covid.
On Friday, a committee of specialists will meet to review the findings and make a recommendation to the FDA. If approved, the Johnson & Johnson vaccine could get the green light by the weekend.
Shares of the company are up roughly half a percent in early trading at $161.20 per share.
Johnson & Johnson predicts that it can deliver 20 million vaccines to the U.S. by the end of March. This which could boost the vaccinated rate for the country by as much as 20%.
Please take a moment to download and subscribe to my free daily podcast here: